Curing and Managing Late Toxicities in Testicular Cancer
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, discusses curing and managing late toxicities in testicular cancer.
Clinical Pearls
Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses curing and managing late toxicities in testicular cancer.
- Drug resistance can be overcome by giving five times the dosage of cytolytic agents. This can be done safely because patients are given back their hematopoietic stem cells by peripheral blood stem-cell transplant.
- Research is being conducted to improve the cure rate of testicular cancer.
- Many young patients who are cured experience complications such as cardiovascular disease and peripheral neuropathy later.
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
